The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing) on Vaginal Innate and Inflammatory Biomarkers.

Trial Profile

The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing) on Vaginal Innate and Inflammatory Biomarkers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Ethinylestradiol/etonogestrel (Primary)
  • Indications Bacterial vaginosis
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2017 Status changed from recruiting to completed, as per results presented at the American Society for Reproductive Medicine Scientific Congress 2017.
    • 01 Nov 2017 Results presented at the American Society for Reproductive Medicine Scientific Congress 2017
    • 23 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top